Jove
Visualize
Contact Us

Related Experiment Videos

Drug interaction studies during drug development: which, when, how?

J Kuhlmann1

  • 1Bayer AG, Pharma Research and Development, Medicine and Development, Institute for Clinical Pharmacology International, Wuppertal, Germany.

International Journal of Clinical Pharmacology and Therapeutics
|June 1, 1994
PubMed
Summary

Selecting drug combinations for interaction studies is crucial during new drug development. Prioritizing based on clinical use and risk ensures efficient and safe drug evaluation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Analytical approaches for MCPD esters and glycidyl esters in food and biological samples: a review and future perspectives.

Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment·2012
Same author

Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer's disease.

Dementia and geriatric cognitive disorders·2012
Same author

Kuntscher intramedullary nail: Use in two specific cases.

Strasbourg medical·2010
Same author

Mapping of phosphorylation-dependent anti-tau monoclonal antibodies in immunoblots using human tau-constructs synthesized by native chemical ligation.

Biochemical and biophysical research communications·2007
Same author

Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response.

British journal of clinical pharmacology·2007
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Pharmacology
  • Drug Development
  • Clinical Trials

Background:

  • Drug-drug interaction (DDI) studies are integral to new drug development.
  • Investigating all potential DDIs is impractical; strategic selection is necessary.

Purpose of the Study:

  • To outline criteria for selecting drug combinations for DDI studies during drug development.
  • To propose an interaction program for new drugs across various therapeutic areas.

Main Methods:

  • Prioritization of DDI studies based on clinical occurrence likelihood and associated risks.
  • Performance of clinical DDI studies typically in late Phase II and Phase III trials.
  • Early-stage DDI studies considered for drugs with narrow therapeutic ranges or interactions affecting vital processes.

Related Experiment Videos

Main Results:

  • Development of a framework for selecting drug combinations for interaction studies.
  • An interaction program was devised for new drugs targeting cardiovascular, respiratory, CNS, rheumatic, metabolic, and infectious diseases.

Conclusions:

  • A risk-benefit and clinical relevance-based approach optimizes DDI study selection.
  • The developed program provides a structured method for assessing potential drug interactions in diverse therapeutic fields.